FDA approved Furoscix ReadyFlow, the first IV-equivalent furosemide auto-injector, enabling rapid, at-home treatment for fluid overload. Clinical data confirmed bioequivalence and safety, with launch set for Q3 2026 and broad adoption expected across care settings.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.